- Home
- AVPT vs CRSP Comparison
AVPT vs CRSP Comparison
Compare AVPT & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVPT
- CRSP
- Stock Information
- Founded
- AVPT 2001
- CRSP 2013
- Country
- AVPT United States
- CRSP Switzerland
- Employees
- AVPT N/A
- CRSP 393
- Industry
- AVPT Computer Software: Prepackaged Software
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVPT Technology
- CRSP Health Care
- Exchange
- AVPT Nasdaq
- CRSP Nasdaq
- Market Cap
- AVPT 3.0B
- CRSP 3.3B
- IPO Year
- AVPT N/A
- CRSP 2016
- Fundamental
- Price
- AVPT $18.85
- CRSP $35.62
- Analyst Decision
- AVPT Buy
- CRSP Buy
- Analyst Count
- AVPT 5
- CRSP 17
- Target Price
- AVPT $17.00
- CRSP $74.53
- AVG Volume (30 Days)
- AVPT 877.0K
- CRSP 2.0M
- Earning Date
- AVPT 05-08-2025
- CRSP 05-06-2025
- Dividend Yield
- AVPT N/A
- CRSP N/A
- EPS Growth
- AVPT N/A
- CRSP N/A
- EPS
- AVPT N/A
- CRSP N/A
- Revenue
- AVPT $349,012,000.00
- CRSP $37,675,000.00
- Revenue This Year
- AVPT $18.61
- CRSP $51.35
- Revenue Next Year
- AVPT $18.52
- CRSP $282.16
- P/E Ratio
- AVPT N/A
- CRSP N/A
- Revenue Growth
- AVPT 21.70
- CRSP N/A
- 52 Week Low
- AVPT $8.06
- CRSP $30.04
- 52 Week High
- AVPT $19.90
- CRSP $67.88
- Technical
- Relative Strength Index (RSI)
- AVPT 77.79
- CRSP 44.74
- Support Level
- AVPT $16.56
- CRSP $33.03
- Resistance Level
- AVPT $17.30
- CRSP $39.38
- Average True Range (ATR)
- AVPT 0.49
- CRSP 1.81
- MACD
- AVPT 0.29
- CRSP -0.19
- Stochastic Oscillator
- AVPT 84.40
- CRSP 33.64
About AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.